Can a type of seaweed really be used to treat Alzheimer’s disease? Some scientists think so, and it’s even being tested in clinical trials today. Oligomannate is extracted from seaweed and can be used as a potential therapy for Alzheimer’s. It is being developed by Shanghai Green Valley Pharmaceuticals and is given conditional approval by China. Now, Oligomannate is in clinical trials in the U.S., Europe and other countries pending approval.
Alzheimer’s disease is a neurodegenerative disease that worsens over time and most commonly leads to dementia. When a brain is healthy, there are numerous nerve cells that connect the brain to different parts of the body. These nerve cells then transfer information back and forth relaying tasks. When a person has Alzheimer’s disease, misfolded proteins, called beta-amyloid, begin to build up and form plaque. This makes it harder for the nerves cells to communicate to the brain.
So how does Oligomannate work to stop these proteins from forming plaque?
In the preclinical studies, oligomannate was able to decrease the build up of beta-amyloid protein in the brain, which in turn can improve cognitive function. Furthermore, oligomannate may be able to regulate the connection between microbiomes from the gut to the brain, reduce harmful metabolites produced by these microbiomes, and lessen inflammation. All of which help to reduce the cause of Alzheimer’s disease.
More research needs to be done before it is FDA approved in the US. Want to play a part in finding a possible treatment for one of the most devastating diseases? Consider participating in a research study! To see what is enrolling, visit our enrolling studies page. Your help is needed to move medicine forward.
Source: Alzheimer’s News Today